Dr. Treon Lecture to Polish Physician's Committee
September, 2013, Krakow, Poland:
Dr Steven Treon, MD, Ph.D, Bing Center for WM, Dana-Farber Cancer Institute; Dr Artur Jurczyszyn MD PhD, Dept of Hematology University Hospital, Krakow Poland; Dr Aleksander B. Skotnicki MD PhD, Dept of Hematology University Hospital, Krakow Poland; Dr Giampolo Merlini MD, Amyloidosis Center, University of Pavia, Italy; Dr David Vesole MD, J Theurer Cancer Center, Hackensack University, NJ, USA; Dr Ruben Niesvizky MD, NY Presbyterian Hospital, Cornell Medical Center, NY, USA; Dr Piotr Boguradzki MD, Warsaw, Poland.
The 2nd International Conference “Complex treatment of plasma cell dyscrasia in 2013” within the country of Poland constitutes a part of the long-term program supporting the concept of interdisciplinary and multimodal therapy of patients with multiple myeloma, amyloidosis, and other plasma cell dyscrasias. With Krakow University Hospital inviting outstanding specialists of various disciplines from many countries, confirms that medicine knows no borders and that mutual intellectual and professional stimulation is above any cultural or national differences.
Outstanding experts in the field of plasma cell, such as Dr Steven Treon, was an honored lecturer and gave a talk on “How I Treat Waldenstrom’s macroglobulinemia in 2013” among a crowd of participating Polish physicians and medical specialists. It was an overwhelming turnout with representatives from around the country, thereby leaving a large, educated impression of knowledge on Waldenstrom’s macroglobulinemia for Eastern European medicine. The lecture was recorded by the Polish Physician’s Committee and can now be seen on the link below:
The presentation is about 36 + minutes long (in English) and begins with an introductory of WM, then Treatment Discussions on NCCN Guidelines, Treatment Evolution in WM (Chlorambucil, Cyclophosphamide, Nucleoside Analogues, IMIDS, Rituximab, CHOP-R, CVP-R, CPR, CDR, BDR, VR, Benda-R, and Everolimus (RAD-001)), and New Directions in WM including Ibrutinib and Carfilzomib.